FIGURE 3.

Prognostic value of hepatocyte growth factor (HGF) and its incremental value to risk scores for outcome prediction. 5-year Kaplan–Meier survival curves for a) the primary combined end-point of death, lung transplant or hospitalisation for acute right heart failure of the total pulmonary arterial hypertension (PAH) cohort (n=197) and b) according to quartiles of HGF levels at baseline. c) Chi-squared of scores and HGF, nerve growth factor (NGF), stem cell growth factor (SCGF)β and stromal cell-derived factor (SDF)1 for prediction of the primary end-point (death, transplant or admission for right heart failure) at 3 years in the total PAH cohort (n=197) using Cox regression. Variables were entered in the model using enter mode. The Mayo right heart score was based on the New York Heart Association (NYHA) functional class, N-terminal pro-brain natriuretic peptide (NT-proBNP) and right ventricular longitudinal strain (RVLS). The Stanford right heart score was based on the NYHA class, NT-proBNP and right ventricular end-systolic remodelling index (RVESRI). The REVEAL score was based on the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) groups: low, average, moderate high, high and very high. *: p<0.05; **: p<0.01.